162.61 USD
-3.51
2.11%
At close Feb 21, 4:00 PM EST
After hours
162.61
+0.00
0.00%
1 day
-2.11%
5 days
-4.01%
1 month
-2.97%
3 months
24.47%
6 months
49.72%
Year to date
13.85%
1 year
18.62%
5 years
336.65%
10 years
628.87%
 

About: Jabil Inc is a United States-based company engaged in providing manufacturing services and solutions. It provides comprehensive electronics design, production and product management services to companies in various industries and end markets.The Company derives its revenue from providing comprehensive electronics design, production and product management services. It operates in two segments. The Electronics Manufacturing Services (EMS) segment, which is the key revenue driver, is focused on leveraging IT, supply chain design and engineering, technologies largely centered on core electronics. The Diversified Manufacturing Services (DMS) segment is focused on providing engineering solutions, with an emphasis on material sciences, technologies, and healthcare.

Employees: 138,000

0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

134% more first-time investments, than exits

New positions opened: 124 | Existing positions closed: 53

44% more funds holding in top 10

Funds holding in top 10: 9 [Q3] → 13 (+4) [Q4]

17% more capital invested

Capital invested by funds: $12.6B [Q3] → $14.8B (+$2.14B) [Q4]

7% more funds holding

Funds holding: 688 [Q3] → 733 (+45) [Q4]

0.97% less ownership

Funds ownership: 92.77% [Q3] → 91.8% (-0.97%) [Q4]

8% less repeat investments, than reductions

Existing positions increased: 247 | Existing positions reduced: 269

11% less call options, than puts

Call options by funds: $434M | Put options by funds: $488M

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$152
7%
downside
Avg. target
$163
0%
upside
High target
$179
10%
upside

4 analyst ratings

positive
75%
neutral
25%
negative
0%
Barclays
George Wang
83% 1-year accuracy
15 / 18 met price target
10%upside
$179
Overweight
Maintained
20 Dec 2024
Stifel
Matthew Sheerin
72% 1-year accuracy
21 / 29 met price target
2%downside
$160
Buy
Reiterated
19 Dec 2024
UBS
David Vogt
42% 1-year accuracy
5 / 12 met price target
7%downside
$152
Neutral
Maintained
19 Dec 2024
Goldman Sachs
Mark Delaney
63% 1-year accuracy
17 / 27 met price target
2%downside
$160
Buy
Maintained
19 Dec 2024

Financial journalist opinion

Based on 11 articles about JBL published over the past 30 days

Positive
Zacks Investment Research
1 day ago
Is Jabil (JBL) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Jabil (JBL) Stock Undervalued Right Now?
Neutral
Zacks Investment Research
1 week ago
Jabil (JBL) Rises Higher Than Market: Key Facts
Jabil (JBL) closed at $167.32 in the latest trading session, marking a +0.48% move from the prior day.
Jabil (JBL) Rises Higher Than Market: Key Facts
Positive
Zacks Investment Research
1 week ago
These 2 Computer and Technology Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
These 2 Computer and Technology Stocks Could Beat Earnings: Why They Should Be on Your Radar
Positive
Zacks Investment Research
2 weeks ago
Jabil (JBL) Surpasses Market Returns: Some Facts Worth Knowing
Jabil (JBL) reachead $163.62 at the closing of the latest trading day, reflecting a +1.11% change compared to its last close.
Jabil (JBL) Surpasses Market Returns: Some Facts Worth Knowing
Neutral
Business Wire
2 weeks ago
Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital and Pharmascience Inc. Announce Exit from Pharmaceutics International, Inc.
NEW YORK--(BUSINESS WIRE)--A consortium of investors led by Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital and Pharmascience Inc. today announced they have exited their equity stake in Pharmaceutics International, Inc. (“Pii”), a contract development and manufacturing organization, and have closed on an undisclosed all-cash transaction to sell the company to Jabil Inc. (NYSE: JBL), a global leader in engineering, manufacturing, and supply chain solutions. Pii is a cont.
Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital and Pharmascience Inc. Announce Exit from Pharmaceutics International, Inc.
Positive
Zacks Investment Research
2 weeks ago
JBL Boosts Healthcare Portfolio With Strategic Buyout: Stock to Gain?
Jabil acquires Pharmaceutics International to enhance commercial prospects in the emerging market of CDMO services.
JBL Boosts Healthcare Portfolio With Strategic Buyout: Stock to Gain?
Positive
Seeking Alpha
2 weeks ago
Jabil: Diversified EMS Stock Is Undervalued
Jabil's diversification in end markets, particularly Auto & Transportation and Healthcare & Packaging, is driving revenue growth despite a 17% YoY decline in Q1 2025. The company's operational diversification, including a broad geographic footprint and supplier base, provides a competitive edge in managing risks and cost efficiency. Jabil's lack of specialization in specific end markets limits its ability to outpace overall EMS market growth, but it maintains stable market share.
Jabil: Diversified EMS Stock Is Undervalued
Neutral
Business Wire
2 weeks ago
Jabil Acquires Pharmaceutics International, Inc. (Pii)
ST. PETERSBURG, Fla.--(BUSINESS WIRE)--Jabil Inc. (NYSE: JBL), a global leader in engineering, manufacturing, and supply chain solutions, today announced the successful acquisition of Pharmaceutics International, Inc. (Pii), a contract development and manufacturing organization (CDMO) specializing in early stage, clinical, and commercial volume aseptic filling, lyophilization, and oral solid dose manufacturing, completed February 3, 2025. “As the pace of healthcare innovation accelerates, pharm.
Jabil Acquires Pharmaceutics International, Inc. (Pii)
Positive
Zacks Investment Research
3 weeks ago
Jabil (JBL) Beats Stock Market Upswing: What Investors Need to Know
Jabil (JBL) closed at $162.64 in the latest trading session, marking a +1.03% move from the prior day.
Jabil (JBL) Beats Stock Market Upswing: What Investors Need to Know
Positive
Zacks Investment Research
3 weeks ago
Here's Why Jabil (JBL) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Jabil (JBL) is a Strong Momentum Stock
Charts implemented using Lightweight Charts™